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ABSTRACT: Retinaldehyde dehydrogenases belong to a
superfamily of enzymes that regulate cell differentiation and
are responsible for detoxification of anticancer drugs. Chemical
tools and methods are of great utility to visualize and quantify
aldehyde dehydrogenase (ALDH) activity in health and disease.
Here, we present the discovery of a first-in-class chemical probe
based on retinal, the endogenous substrate of retinal ALDHs.
We unveil the utility of this probe in quantitating ALDH
isozyme activity in a panel of cancer cells via both fluorescence
and chemical proteomic approaches. We demonstrate that our
probe is superior to the widely used ALDEFLUOR assay to explain the ability of breast cancer (stem) cells to produce all-trans
retinoic acid. Furthermore, our probe revealed the cellular selectivity profile of an advanced ALDH1A1 inhibitor, thereby
prompting us to investigate the nature of its cytotoxicity. Our results showcase the application of substrate-based probes in
interrogating pathologically relevant enzyme activities. They also highlight the general power of chemical proteomics in driving
the discovery of new biological insights and its utility to guide drug discovery efforts.
■ INTRODUCTION
All-trans retinoic acid (ATRA), the bioactive form of vitamin
A, regulates many cellular and physiological functions,
including embryonic development, immunomodulation, neuro-
nal differentiation, and (cancer) stem cell proliferation.1−4
Most of the cellular functions of ATRA are mediated via its
binding to the retinoic acid receptor (RAR), which forms
heterodimers with the retinoid X receptor (RXR). Binding of
ATRA to the RAR/RXR heterodimer complex modulates gene
transcription by recruiting different cofactors to the DNA-
bound complex in a cell specific manner.5,6 ATRA is essential
for living organisms, and disruption of ATRA signaling leads to
severe (neural) developmental defects, autoimmunity disor-
ders, and cancer. The key function of ATRA in biological
signaling implies that its cellular levels are tightly regulated.
ATRA is formed by two-step oxidation of its precursor
retinol, which is taken up from the diet.7 Retinol is converted
to retinal in a reversible manner by alcohol dehydrogenases.
Retinal is subsequently oxidized to ATRA by retinaldehyde
dehydrogenases in an irreversible and rate limiting step. Three
retinaldehyde dehydrogenases (i.e., ALDH1A1, ALDH1A2,
and ALDH1A3), which belong to a superfamily of 19 aldehyde
dehydrogenases (ALDHs), produce ATRA from retinal in a
cell specific manner.8,9 Noteworthy, ALDH1A1 and
ALDH1A3 have also been reported as cancer stem cell
biomarkers,10 and ALDH1A1 activity may confer resistance
against chemo- and radiation therapy.11−13
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The ability to discern the contribution of specific
retinaldehyde dehydrogenases to the global ALDH activity is
necessary to understand the underlying biology and develop
effective anticancer therapies. Retinaldehyde dehydrogenases
have a variable and inducible cellular expression pattern. Their
activity is regulated by protein−protein interactions and post-
translational modifications.14,15 Immunoblotting and quantita-
tive real-time polymerase chain reaction (RT-PCR) are
currently used to determine retinaldehyde dehydrogenase
expression in cells, but these assays report solely on protein
expression levels and not on activity.16,17 The ALDEFLUOR
assay does report on global ALDH activity levels in (cancer)
stem cells. This assay uses a fluorescent aldehyde that upon
oxidation to a fluorescent carboxylate remains trapped within
cells. However, the ALDEFLUOR assay does not discriminate
between individual ALDHs.18 Recently developed selective
fluorescent substrates report on the activity of a single enzyme
but do not provide an overview of the global ALDH activity
present in a biological system.19,20 The development of
chemical tools and methods to profile cellular retinaldehyde
dehydrogenase activity is, therefore, important to study ATRA
signaling in cancer (stem) cells and the discovery of effective
molecular therapeutic strategies.
Selective ALDH inhibitors are required to study the
physiological role of retinaldehyde dehydrogenases in cancer
cells in an acute and dynamic matter and may serve as
potential drug candidates. Most reported ALDH inhibitors,
such as disulfiram, 4-diethylaminobenzaldehyde (DEAB),
citral, and gossypol, however, are weakly active and/or
demonstrate promiscuous behavior, which complicates the
interpretation of their biological effects.8,21 Analogues of the
natural product duocarmycin have been shown to target
ALDH1A1.22 Recently, NCT-505 was developed as one of the
first promising, potent ALDH1A1 inhibitors with a >1000-fold
selectivity over ALDH1A3 as determined in a biochemical
assay.23 NCT-505 was cytotoxic to ovarian cancer cells and
sensitized them to paclitaxel. The cellular selectivity profile and
its mode-of-action have not been reported yet, which would be
of importance to guide its therapeutic development.
The determination of target protein engagement and off-
target activities of small molecules is an essential step in drug
discovery. Activity-based protein profiling (ABPP) has become
one of the key methodologies to map the interactions of
inhibitors and enzymes on a global scale in living systems, such
as cells and animals.24,25 ABPP is a technology that relies on
activity-based chemical probes that covalently and irreversibly
Figure 1. Design and synthesis of the retinal-based probe LEI-945. (a) Enzymatic conversion of retinal to retinoic acid by ALDH1A1. Nucleophilic
attack of the cysteine on the aldehyde of retinal resulting in a hemithioacetal. Hydride abstraction by nicotinamide adenine dinucleotide (NAD+)
results in a thioester which is consequently hydrolyzed releasing the product. (b) Docking pose of retinal probe LEI-945 in crystal structure of
ALDH1A1 (PDB: 4WP7) showing the location of interaction between the vinyl ketone warhead and the catalytic cysteine (C303). (c) Docking
pose of retinal probe LEI-945 in crystal structure of ALDH1A1 (PDB: 4WP7) showing the ligation handle solvent exposed. (d) Synthesis of
activity-based probe LEI-945. Reagents and conditions: (a) NBS, AIBN, CCl4, 80 °C, 2 h, then Na2CO3, DMF, 81% over two steps; (b) H2SO4,
propargyl alcohol, 4 °C, 18 h, 23%; (c) vinylmagnesium bromide, THF, 18 h, quant.; (d) PPh3HBr, 18 h, 78%; (e) trimethyl orthoformate, pTsOH,
MeOH, 2 h, quant.; (f) N,O-dimethylhydroxylamine hydrochloride, i-PrMgCl, THF, 3 h, quant.; (g) TFA, DCM/H2O, 2 h, quant.; (h) 9, n-BuLi,
THF, −78 °C to rt, 2 h, 46%; (i) vinyl magnesium bromide, THF, 2 h, 43%.
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react with the catalytic nucleophile in the active site of an
enzyme in their native biological context.26 Since this process
requires a catalytically active protein, these chemical probes
report on the abundance of active enzymes. ABPP enables the
determination of target engagement and selectivity profiling of
drug candidates in their physiological relevant environment,
which enhances the therapeutic relevance of the observed
interaction profile.27−29 An activity-based probe (ABP)
generally consists of an electrophilic warhead, a scaffold that
recognizes the protein (family) of interest, and a fluorophore
or biotin as reporter group. ABPP has found successful
applications in detecting, among others serine hydrolases,26,30
proteases,31 kinases,32 and glycosidases.33 However, to date no
ABP for retinaldehyde dehydrogenases has been developed,
despite the fact that the catalytic mechanism employed by
these enzymes during substrate processing involves a covalent
intermediate.
Here, we describe the design, synthesis, biological validation,
and application of the retinal-based ABP LEI-945, featuring a
vinyl ketone warhead and an alkyne ligation handle for the
introduction of reporter groups. LEI-945 is a first-in-class
probe that enables profiling retinaldehyde dehydrogenases in
cancer cells. Comparative chemical proteomics with LEI-945
explained the ability of various breast cancer cell lines to
produce ATRA via specific ALDH isozymes, whereas the
ALDEFLUOR assay could not. Competitive chemical
proteomics using LEI-945 was employed to determine the
cellular target engagement and selectivity profile of NCT-505
in MDA-MB-468 breast cancer cells. We found that both
ALDH1A1 and ALDH1A3 were inhibited by NCT-505
resulting in an overall reduced cell viability caused by a cell
cycle arrest and necrosis-induced cell death. Our results show
that LEI-945 holds promise to guide the discovery of ALDH-
based therapeutics.
■ RESULTS AND DISCUSSION
Design and Synthesis of the Retinal-Based Probe LEI-
945. Retinaldehyde dehydrogenases convert their substrate
through nucleophilic attack of the catalytic cysteine thiol on
the aldehyde yielding a hemithioacetal (Figure 1a). Hydride
abstraction by nicotinamide adenine dinucleotide (NAD+)
with concomitant deprotonation results in net dehydrogen-
ation and formation of a thioester adduct.8 Hydrolysis of this
thioester by a water molecule leads to the formation of ATRA.
We sought to take advantage of the fact that covalent enzyme−
substrate intermediates emerge during catalysis by designing an
ABP based on the structure of retinal. We hypothesized that
the aldehyde in retinal could be exchanged with a vinyl ketone
to trap the nucleophilic catalytic cysteine through conjugate
addition (Figure 1b). Docking of such a retinal-derived vinyl
ketone into the crystal structure of ALDH1A1 (PDB: 4WP7)34
suggested that the nucleophile (the catalytic cysteine thiol) and
the electrophile (the unsaturated ketone) would be in close
proximity. It pointed as well to a suitable position, which is a
solvent exposed position where probe contact with the enzyme
active site is negligible, for installation of a bioorthogonal
ligation handle (Figure 1c). An alkyne ligation handle was
selected since it minimally affects the lipophilicity and
physicochemical properties of the probe.35,36 This led to the
design of LEI-945 as a potential two-step retinaldehyde
dehydrogenase ABP (Figure 1d).
Figure 2. In situ labeling of ALDH by LEI-945 and competition with inhibitors. (a) In situ labeling of ALDH1A1, ALDH1A2, and ALDH1A3
transiently transfected in U2OS cells using LEI-945 (1 μM) for 1 h at 37 °C and anti-FLAG Western blot. Competition was performed with
natural substrate retinal (100 μM) or general ALDH inhibitor DEAB (100 μM). (b) In situ labeling of ALDH1A3WT and mutant ALDH1A3C314A
with LEI-945 (1 μM) for 1 h at 37 °C and anti-FLAG Western blot. (c) In situ labeling of endogenous ALDH enzymes in A549 lung cancer cells
with LEI-945 (1 μM) and competition with ALDH inhibitors or natural substrate. (d) Table showing the pIC50 values ± SD of several ALDH
inhibitors as determined by competitive ABPP with probe LEI-945 (1 μM) in three experiments. (e) Chemical structures of ALDH inhibitors used
in this study.
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LEI-945 was synthesized using a convergent synthesis
scheme starting from commercially available β-ionone 1 and
ethyl 3-methyl-4-oxocrotonate 6 (Figure 1d). Bromination of 1
using NBS, followed by dehydrobromination of 3-bromo-β-
ionone with Na2CO3, afforded 3-dehydro-β-ionone 2 in 81%
yield. Conjugate addition of propargyl alcohol to 3-dehydro-β-
ionone 2 following a modification of the literature procedure37
provided alkyne 3 in 23% yield. Grignard reaction of 3 and
vinylmagnesium bromide quantitatively afforded tertiary
alcohol 4. Addition of triphenylphosphine hydrobromide in
methanol provided phosphonium salt 5 in 78% yield.38
Intermediate 9 required for the key Wittig reaction toward
the retinal scaffold was made from commercially available ethyl
3-methyl-4-oxocrotonate 6 as follows. Treatment of 6 with
trimethyl orthoformate and catalytic acid yielded acetal 7 in
quantitative yield. The ester in 7 was converted into Weinreb
amide 8 using N,O-dimethylhydroxylamine hydrochloride also
in quantitative yield. The acetal in 8 was quantitatively
deprotected using aqueous TFA, yielding aldehyde 9.
Phosphonium salt 5 was deprotonated at −78 °C using n-
BuLi after which addition of aldehyde 9 and stirring at room
temperature afforded compound 10. Finally, treatment of
Weinreb amide 10 with vinylmagnesium bromide furnished
LEI-945 in 20% yield over the last two steps.
Retinal-Based Probe LEI-945 Maps ALDH Activity in
Living Cells. To assess whether LEI-945 acts as a
retinaldehyde dehydrogenase ABP, pcDNA3.1 plasmids
containing either recombinant human ALDH1A1,
ALDH1A2, or ALDH1A3 fused to a FLAG-tag were
transiently transfected in human osteosarcoma U2OS cells.
Living cells were treated with LEI-945 (1 μM) in serum-free
medium for 1 h, lysed, and treated with Alexa Fluor 647 dye
under copper(I)-catalyzed azide−alkyne [2 + 3] cycloaddition
conditions. The protein samples were resolved by sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and visualized by in-gel fluorescent scanning. A
fluorescent band at 55 kDa was apparent in samples harvested
from three transfected cell cultures, but not in the mock-
treated cells (Figure 2a). All fluorescent bands were at the
same height as the signal generated by using an anti-FLAG
antibody in a separate Western blotting experiment. This
molecular weight matches with that of the transfected
retinaldehyde dehydrogenases, suggesting that LEI-945 indeed
reacted with these in a covalent manner. Fluorescent labeling
intensity was reduced by pretreatment (1 h) with retinal (100
μM) as well as with the general ALDH inhibitor, DEAB (100
μM) (Figure 2a).39 Site-directed mutagenesis of the catalytic
Cys314 into alanine in ALDH1A3, which was chosen as a
representative retinaldehyde dehydrogenase, abolished labeling
Figure 3. Proteomics data of retinaldehyde interacting proteins in A549 cells. (a) Fold-change (LEI-945: DMSO) plot for total proteins identified
in chemical proteomics experiment with probe LEI-945 (1 μM). Red lines indicates the threshold fold-change of 2-fold enrichment and the
maximum fold-change is set at 20. Red dots represent significantly enriched ALDH enzymes. (b) Volcano plot for total proteins identified in
chemical proteomics experiment with probe LEI-945 (1 μM). Red lines indicate threshold values (fold-change >2; p-value <0.05) marking
significantly enriched proteins. Red dots represent significantly enriched ALDH enzymes. (c) Subcellular localization of significantly enriched
proteins as annotated by the UniProt database. (d) Molecular functions attributed to significantly enriched proteins by the Panther database. (e)
Top 6 pathways enriched in the group of significantly enriched proteins as determined by screening on the KEGG database. (f) Maximum
abundance (white = low; blue = high) and inhibition (blue = 0%; red = 100%) by pan-ALDH inhibitor DEAB (100 μM) and natural substrate
retinal (100 μM) in competitive ABPP experiments with LEI-945. For parts a, b, and f, data are from n = 4 experiments (biological replicates). (g)
In situ labeling of ALDH3A2 and EPHX1 transiently transfected in U2OS cells using LEI-945 (1 μM) for 1 h at 37 °C.
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of the enzyme with LEI-945, whereas protein expression was
not affected as determined by FLAG-tag antibody (Figure 2b).
A liquid chromatography−mass spectrometry assay was
developed to measure the conversion of retinal into ATRA
by ALDHs. Overexpressing ALDH1A3WT and ALDH1A3C314A
in U2OS in combination with this assay confirmed that
Cys314 was required for the enzymatic activity of ALDH1A3
(Figure S7). Together, these data demonstrate that LEI-945
efficiently labels ALDH1A1, ALDH1A2, and ALDH1A3 in an
activity-dependent manner by forming an irreversible covalent
bond with the catalytic cysteine.
To establish the potential of LEI-945 to detect endogenous
retinaldehyde dehydrogenases, we incubated the non-small-cell
lung cancer cell line A549, known to express ALDH1A1,16,40
with LEI-945. This yielded a fluorescent band at around 55
kDa, which could be significantly and dose-dependently
reduced by preincubation with either DEAB, disulfiram,8
STA-186, or retinal, with pIC50 in the range 5.0−5.9 (Figure
2c,d). To find out which proteins are irreversibly and
covalently labeled by LEI-945, a label-free chemical
proteomics experiment was performed. LEI-945 (1 μM, 1
h)-treated A549 cells were lysed and reacted with biotin-N3,
after which probe-labeled proteins were enriched by
streptavidin bead pull-down. Subsequent trypsin digestion,
protein identification, and quantification by mass spectrometry
resulted in the identification of 34 significantly enriched
proteins, including ALDH1A1, ALDH2, ALDH3A2, and
ALDH3B1 (Figure 3a,b and Table S1). To exclude the
possibility that the warhead covalently binds to reactive
cysteines irrespective of recognition based on the retinal
scaffold, we compared our list of 34 significantly enriched
proteins with a list of the 150 most reactive cysteines. This list
was compiled by Cravatt et al.41 using ABPP with the reactive
nucleophile iodoacetamide in MDA-MB-231, MCF7, and
Jurkat cancer cell lines. Only two proteins (ALDH2 and
RTN3) from this list were identified as interacting partners of
LEI-945. This suggested that the scaffold of LEI-945 confers
selectivity to its binding partners and does not randomly label
proteins with hyperreactive cysteines. Some of the enriched
proteins have been previously reported to interact with
retinoids and related lipids, such as sarcoplasmatic/endoplas-
mic reticulum calcium ATPase 2 (ATP2A2), ADP/ATP
Figure 4. Profiling levels of active ALDH proteins in breast cancer cell lines. (a) Mean fluorescence intensity (MFI) of ALDH activity measured in
breast cancer cell lines using the ALDEFLUOR assay. Data are represented as mean values ± SD; N = 3 independent experiments with each n = 3
experiments per group (biological replicates). (b) Retinoic acid production by breast cancer cell lines. Data represent mean values ± SD; N = 3
experiments (biological replicates) measured twice. (c) ALDH profiling of breast cancer cell lines using chemical proteomics. The subtype column
indicates if the cell line belongs to the luminal subtype (white) or basal subtype (black). The retinal converted column shows the amount of retinal
converted to retinoic acid over 4 h in a gradient from 0% (white) to 100% (red). The ALDEFLUOR column shows the ALDH activity as
determined by the ALDEFLUOR assay in a gradient from low (white) to high (red). The heatmap shows the fold-change in LFQ value for each
ALDH enzyme compared to the average for each ALDH enzyme. N = 2 independent experiments with each at least n = 3 experiments per group
(biological replicates). (d) Correlation of transcriptomics data with ABPP data. ALDHs measured in cell lines with a basal subtype are shown as red
dots, and the ones with a luminal subtype are shown as black dots and the Pearson’s correlation reported for the correlation between ABPP and
transcriptomics (r = 0.8005; p = 0.0003). Dotted lines represent the 95% confidence interval. (e) Correlation of proteomics data with ABPP data.
ALDHs measured in cell lines with a basal subtype are shown as red dots, and the ones with a luminal subtype are shown as black dots and the
Pearson’s correlation reported for the correlation between ABPP and proteomics (r = 0.7388; p = 0.0003). Dotted lines represent the 95%
confidence interval.
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translocase 2 (SLC25A5), ADP/ATP translocase 3
(SLC25A6), voltage-dependent anion-selective channel pro-
tein 2 (VDAC2), and voltage-dependent anion-selective
channel protein 3 (VDAC3).42−45 Pathway analysis using the
KEGG,46 UniProt,47 and Panther48 databases and DAVID49
analytic tools revealed that most enzymes and transporters are
located in the endoplasmic reticulum and mitochondria
(Figure 3c). A significant number of unannotated proteins
were found, and we suggest that these proteins may be
involved in retinal/retinoic acid biochemistry and biology
(Figure 3d). Many proteins involved in fatty acid degradation,
β-alanine, and histidine metabolism were enriched, which is in
line with the proposed role of ALDH enzymes in these cellular
functions (Figure 3e).8 To investigate whether these proteins
are also targeted by retinal and DEAB, we performed a
competitive chemical proteomics experiment (Figure 3f).
Retinal inhibited over 85% of the targets of LEI-945, including
all identified ALDH enzymes apart from ALDH2, whereas
DEAB was much more selective and reduced the labeling of
only three proteins (ALDH1A1, ALDH2, and PCNA-
interacting partner (PARPBP)). To validate the identified
probe targets as retinoid-interacting proteins, we overexpressed
recombinant ALDH3A2 and epoxide hydrolase 1 (EPHX1) as
representative examples in U2OS cells and fluorescently
labeled them with LEI-945 (1 μM). Competition with retinal
(100 μM) confirmed their ability to bind retinoids (Figure 3g).
Taken together, these data show that LEI-945 enables the
detection of various retinaldehyde dehydrogenases and other
retinoid-interacting proteins in living human cells. Having
established the efficacy and specificity of LEI-945, the probe
was subsequently used in comparative and competitive ABPP
studies as detailed in the next sections.
LEI-945 Reveals Distinct ALDH Activities in Cells of
Different Breast Cancer Subtypes. ALDH activity in breast
cancer cells has been linked with chemo- and radiotherapy
resistance.13 For example, the presence of ALDH1A1 has been
found to correlate with resistance in cancer tissue toward
cyclophosphamide, and the expression of ALDH1A3 is
associated with poor clinical outcome in breast can-
cer.11,12,17,50,51 To determine whether LEI-945 can be used
to profile the activities of these ALDHs in breast cancer cell
lines, a panel of seven breast cancer cell lines was selected
ranging from aggressive basal origin (MDA-MB-231, BT-20,
MDA-MB-468, and HCC38) to less aggressive luminal origin
(SK-BR-7, MCF7, and SK-BR-3).52 Their general ALDH
activity was measured using the ALDEFLUOR assay.53 Based
on this assay the breast cancer cell lines were divided into two
groups: ALDHhigh (BT-20, MDA-MB-468, and SK-BR-3) and
ALDHlow (MDA-MB-231, SK-BR-7, HCC38, and MCF7)
(Figure 4a). The two groups did not correlate with the breast
cancer subtype.
Next, we determined the capability of the breast cancer cell
lines to convert retinal into ATRA by liquid chromatography/
mass spectrometry. Retinal (10 μM, 1 h)-treated cells were
lysed and the lipids extracted after which the unique UV
absorption of the retinoids relative to other metabolites was
used to determine to which extent retinal was converted
(Figure 4b). The results of the ALDEFLUOR assay (Figure
Figure 5. Physiological effects and target engagement of NCT-505 in MDA-MB-468 cells. (a) Chemical structure of ALDH1A1 inhibitor NCT-
505. (b) Cell viability of MDA-MB-468 cells after treatment with NCT-505 (30 μM) for 72 h. (c) Cell proliferation of breast cancer cell lines after
treatment with NCT-505 (30 μM) for 72 h. For parts b and c, data represent mean values ± SD; N = 3 biological replicates with each n = 3
experiments per group. ***P < 0.001; ****P < 0.0001; t test, two-sided. (d) Volcano plot of the in situ competitive ABPP experiment in MDA-
MB-468 to determine off-targets of ALDH inhibitor NCT-505 (30 μM). N = 4 experiments per group (biological replicates). (e) Relative ATP
levels of vehicle and NCT-505 (30 μM)-treated MDA-MB-468 cells as determined by CellTiter-Glo assay. Data represent mean values ± SD; N =
3 biological replicates with each n = 3 experiments per group. ****P < 0.0001. (f) Relative mitochondrial membrane potential (ΔΨm) of vehicle
and NCT-505 (30 μM)-treated MDA-MB-468 cells visualized by Rhodamine 123 and measured over time. (g) Distribution over the different cell
cycle phases of vehicle and NCT-505 (30 μM)-treated FUCCI-expressing cells MDA-MB-468 after 72 h. (h) Cell death profile of vehicle and
NCT-505 (30 μM)-treated MDA-MB-468 cells as determined by propidium iodide (PI) staining and measured over time. For parts f−h, data
represent mean values ± SD; N = 3 biological replicates with each 5 experiments per group. *P < 0.05; **P < 0.01; t test, two-sided. (i) Synergy
between RSL3 (30 nM) and NCT-505 (3 μM) measured using a viability assay after 72 h of treatment. Data represent mean values ± SD; N = 3
biological replicates with each 6 experiments per group. ****P < 0.0001.
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4a) did not correlate with the ability of cells to produce ATRA
from retinal. For example, while MDA-MB-468 and SK-BR-3
were both classified as ALDHhigh, only MDA-MB-468 cells
produced significant amounts of ATRA. We hypothesized that
ABPP using LEI-945 would be able to explain these apparent
contradictory results by determining the levels of active
retinaldehyde dehydrogenases in each breast cancer cell line.
Chemical proteomics experiments were performed with
samples from all seven breast cancer cell lines using LEI-945
(1 μM, 1 h) (Figure 4c). ALDH1A1 was found in SK-BR-7
and MDA-MB-468. ALDH1A3 was detected in BT-20, MDA-
MB-468, and SK-BR-3. ALDH2 was significantly enriched in
MDA-MB-231, HCC38, MDA-MB-468, and SK-BR-3.
ALDH3A2 was identified in MDA-MB-231, SK-BR-7, BT-20,
MDA-MB-468, and SK-BR-3. Comparison of the chemical
proteomics data with data from transcriptomics and global
proteomics experiments of these breast cancer cell lines
revealed in general a high correlation with r of 0.80 and 0.74
between enzyme activity and mRNA and protein levels,
respectively (Figure 4d,e). Levels of active ALDH1A1 and
ALDH1A3 enzymes were higher than expected on the basis of
the mRNA and protein levels, indicating that the activity of
these enzymes is potentially regulated post-translationally, as
was previously reported.14,15 Active ALDH1A1 was most
abundant in the MDA-MB-468 cells, whereas SK-BR-3 had
high levels of active ALDH2 and no discernible levels of active
ALDH1A1. Since ALDH2 does not convert retinal into
retinoic acid,54 but is an efficient oxidizer of numerous
aldehydes, these data may explain the discrepancy between the
ALDEFLUOR assay and the retinal conversion assay. Taken
together, our data show that LEI-945 has the ability to identify
individual ALDH isozyme activities in cancer cells and report
on the well-known cancer biomarkers ALDH1A1 and
ALDH1A3.10
NCT-505 Inhibits ALDH1A1 and ALDH1A3 in MDA-
MB-468 Cells. For successful drug discovery it is essential to
understand the molecular and cellular mode-of-action of a drug
candidate. So far, studies on the physiological effects of ALDH
inhibition in cancer have been mostly performed with poorly
active and/or promiscuous inhibitors, which have not been
properly characterized in biological systems.13,21,40,55,56
This complicates the interpretation of the physiological
function ascribed to a specific ALDH. Here, we used LEI-945
to study the cellular ALDH interaction profile of the
ALDH1A1 inhibitor NCT-505 (Figure 5a). First, we
confirmed that NCT-505 was able to significantly reduce cell
viability and proliferation of MDA-MB-468 cells, which
expressed the highest levels of ALDH1A1 (Figure 5b,c). To
determine the cellular target engagement and off-target
activities, we performed a chemical proteomics experiment
with LEI-945 using MDA-MB-468 cells in situ treated with
NCT-505. This competitive ABPP experiment showed that
both ALDH1A1 and ALDH1A3 were inhibited by NCT-505
at the concentration used in the cell viability and proliferation
assay (Figure 5d). Putative heat shock protein HSP 90-beta-3
(HSP90AB3P), the aryl hydrocarbon receptor (AHR), and
chitobiosyldiphosphodolichol beta-mannosyltransferase
(ALG1) were also identified as off-targets of NCT-505.
Having established the cellular retinaldehyde dehydrogenase
interaction profile of NCT-505 by ABPP using LEI-945, we
further characterized the biological effects of this dual
ALDH1A1/ALDH1A3 inhibitor in MDA-MB-468 cells.
NCT-505 produced a limited, but significant, reduction in
ATP levels (Figure 5e). Mitochondrial membrane potential
(ΔΨm) upon preincubation of MDA-MB-468 cells was also
reduced as assessed with Rhodamine 123, a fluorescent marker
for mitochondrial activity, suggesting that mitochondrial
function was altered (Figure 5f and Figure S13B). In addition,
exposure to NCT-505 arrested cells in the G1 cycle as
determined by fluorescent ubiquitination-based cell cycle
indicators (FUCCIs) (Figure 5g and Figure S14).57 The
nuclei of the NCT-505-treated cells were highly condensed
compared to vehicle-treated cells indicating dying cells, which
had no Rhodamine 123 signal as well (Figure S15 and arrows
in Figure S13B). A significant increase in the fraction of
propidium iodide positive cells was observed in NCT-505-
treated cells, which suggested that the cells underwent necrosis
(Figure 5h and Figure S13A). As changes in mitochondrial
morphology are a distinctive feature of ferroptosis,58 the
observed nonapoptotic cell death in combination with
alterations in mitochondrial function might indicate that the
cells die undergoing ferroptosis. We therefore tested whether
incubation with RSL3, a compound that induces ferroptosis via
inhibition of GPX4,59,60 and inhibition of ALDH1A1/
ALDH1A3 could synergistically induce cell death. MDA-MB-
468 cells treated separately with ineffective, low concentrations
of GPX4 inhibitor RSL3 (30 nM) or NCT-505 (3 μM) did not
show any reductions in cell viability, whereas the combination
led to a significant decrease in cell viability (Figure 5i) with a
combination index value of 0.87 indicating synergism (Figure
S16).
■ CONCLUSION
In this study we present the first rationally designed, retinal-
based probe LEI-945 specifically developed for the profiling of
retinaldehyde dehydrogenases. We demonstrated that LEI-945
inhibits ALDH1A1, ALDH1A2, and ALDH1A3 in an activity-
based dependent manner via irreversible covalent reaction of
the catalytic cysteine and is able to detect endogenously
expressed ALDH isozyme activities in various (breast) cancer
cells, but also for the identification of retinoid-interacting
proteins in living cells. To date only a few probes for oxidases
have been reported61−63 and only one retinoid-based probe.64
This retinyl ester-based probe labeled two retinyl ester
processing enzymes in retinal pigment epithelial membrane,
but did not label ALDHs.65 To our knowledge, LEI-945
represents, therefore, the first-in-class probe for aldehyde
dehydrogenases that enables cellular profiling of ALDH activity
as cancer (stem) cell biomarkers and target engagement
studies for drug discovery of this target family in drug-resistant
cancer cells.
LEI-945 was able to detect and compare individual active
ALDH isozymes in breast cancer cell lines. The ALDH profiles
generated using LEI-945 could be used to explain the ability of
certain cell lines to produce retinoic acid, where the
ALDEFLUOR assay could not. It also detected levels of active
ALDH1A1 enzyme in the SK-BR-7 cell line, while the
ALDEFLUOR assay reported no ALDH activity. We propose
that our method can be used in combination with the
ALDEFLUOR assay by sorting cells based on global ALDH
activity and subsequently subjecting the sorted cell populations
to comparative ABPP analysis, thus, providing both qualitative
and quantitative information on the levels of active ALDH
enzymes in therapy-resistant cancer (stem) cells enabling a
better mechanistic understanding of the underlying biology,
which is ALDH isozyme-dependent.66
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Furthermore, we showed that LEI-945 enabled target
engagement and cellular selectivity studies of the recently
reported ALDH1A1 inhibitor NCT-505. Our ABPP method
revealed that NCT-505 inhibits not only ALDH1A1 but also
ALDH1A3, at concentrations that significantly reduced cell
viability and proliferation of MDA-MB-468 cells via inhibition
of mitochondrial function, cell cycle arrest in the G1 phase,
and necrosis-induced cell death. The concentration used in this
study is in accordance with the reported EC50 value derived
from OV-90 ovarian cancer cells grown in 2D cell culture.23
Maloney et al. showed an increase in sensitivity toward NCT-
505 when cells are grown in 3D cell culture, possibly due to the
accompanying elevated levels of ALDH1A1 expression.23
Elevated ALDH expression in 3D cell culture compared with
2D has also been described by others.67,68 This phenomenon
could be studied in more depth by looking at changes in the
levels of active enzymes using LEI-945. Ferroptosis induced
via GPX4 inhibition was synergistic with NCT-505-mediated
toxicity. This combined therapy is of interest as both
therapeutic targets, GPX4 and ALDH1A1, have been linked
to therapy resistance in cancer.56,59,60 Since both enzymes are
involved in the detoxification of lipid peroxidation products,
this might explain the observed synergistic effect.69−71 Since
NCT-505 inhibits also ALDH1A3, our data do not rule out the
possibility that ALDH1A3 may also be an interesting drug
target to tackle drug resistance in cancer. To conclude, LEI-
945 is a first-in-class retinal probe capable of the activity-based
profiling of retinaldehyde dehydrogenases, which can be used
for comparative and competitive ABPP of cancer cells and
ALDH inhibitors, thereby providing guidance in the target
validation and discovery of cancer (stem) cell-based therapies.
Thus, these results showcase the application of substrate-based
probes in interrogating pathologically relevant enzyme
activities. They also highlight the general power of chemical
proteomics in driving the discovery of new biological insights
and guiding drug discovery efforts.
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